B. In the Claims

Please amend claims 19, 21, 25, 26, 30, 31, 32, 36 and 37, cancel claims 1 to 18 without prejudice, and add new claims 38 and 39.

Upon entry of the present amendment, the status of the claims will be as follows:

Claims 1 to 18 (canceled).

19. (Currently amended) An antibody that binds to ~~the FHF polypeptide of claim 1~~ a substantially pure fibroblast growth factor homologous factor-4 (FHF-4) polypeptide.

20. (Original) The antibody of claim 19, wherein the antibody is monoclonal.

21. (Currently amended) A method of detecting a cell proliferative disorder associated with expression of ~~the FHF~~ a fibroblast growth factor homologous factor-4 (FHF-4) polypeptide ~~of claim 1~~, the method comprising the steps of:

a. contacting a specimen from a subject having or suspected of having the disorder with a reagent that detects expression of the ~~FHF~~ FHF-4 polypeptide~~,~~; and

b. detecting binding of the reagent to the specimen.

22. (Original) The method of claim 21, wherein the cell is a brain cell.

23. (Original) The method of claim 21, wherein the reagent is an antibody.

24. (Original) The method of claim 21, wherein the reagent is a nucleic acid.

25. (Currently amended) The method of claim 24, wherein the nucleic acid hybridizes to ~~the nucleic acid of claim 8~~ a nucleic acid encoding the FHF-4 polypeptide.

26. (Currently amended) The method of claim 24, wherein the nucleic acid hybridizes to the complement of ~~the nucleic acid of claim 8~~ a nucleic acid encoding the FHF-4 polypeptide.

27. (Original) The method of claim 21, wherein the detecting is carried out *in vivo*.

28. (Original) The method of claim 21, wherein the detecting is carried out *in vitro*.

29. (Original) The method of claim 21, wherein the reagent comprises a detectable label.

30. (Currently amended) A method of treating a cell proliferative disorder associated with expression of ~~the FHF~~ a fibroblast growth factor homologous factor-4 (FHF-4) polypeptide ~~of claim 1~~, the method comprising administering to a subject having or suspected of having the disorder a reagent that suppresses the activity of the FHF polypeptide.

31. (Currently Amended) The method of claim 30, wherein the reagent is an ~~anti-FHF~~ anti-FHF-4 antibody.

32. (Currently amended) The method of claim 30, wherein the reagent is a nucleic acid that hybridizes to ~~the nucleic acid of claim 8~~ a nucleic acid encoding the FHF-4 polypeptide.

33. (Original) The method of claim 30, wherein the cell is a brain cell.

34. (Original) The method of claim 30, wherein the reagent is introduced into the cell using a carrier.

35. (Original) The method of claim 34, wherein the carrier is a vector.

36. (Currently Amended) A method of identifying a nucleic acid encoding ~~an FHF~~ a fibroblast growth factor homologous factor-4 (FHF-4) polypeptide, the method comprising probing a sample containing a nucleic acid encoding ~~an FHF~~ the FHF-4 polypeptide with an ~~FHF-specific~~ FHF-4-specific nucleic acid probe.

37. (Currently amended) The method of claim 36, wherein the ~~FHF-specific~~ FHF-4-specific nucleic acid probe hybridizes to:

a. a nucleic acid that encodes seven consecutive amino acids, at least four of which are conserved in the amino acid ~~sequences of FHF-1 (SEQ ID NO:1), FHF-2 (SEQ ID NO:2), FHF-3 (SEQ ID NO:3), and~~ sequence of FHF-4 (SEQ ID NO:4)~~,~~; or

b. the complementary sequence thereto.

38. (New) The antibody of claim 19, wherein FHF-4 polypeptide

a. is about 225-250 amino acids in length;

b. lacks an amino terminal signal sequence; and

c. contains a nuclear localization signal.

39. (New) The antibody of claim 19, wherein the FHF-4 polypeptide comprises a segment of at least five consecutive amino acids that are conserved in the amino acid sequence of FHF-4 (SEQ ID NO:4).